Tacrolimus and Risk Factors for Glucose Metabolism Disorders in Kidney Transplant Patients

RecruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

May 29, 2025

Primary Completion Date

October 30, 2027

Study Completion Date

January 30, 2028

Conditions
Kidney Transplant
Interventions
DRUG

LCP Tacro (tacrolimus)

Treatment with LCP Tacro will begin on the day of the kidney transplant. If a patient is switching from another form of tacrolimus to LCP Tacro, the transition will be completed no later than day 8, following the standard procedures of the medical institution.

Trial Locations (6)

80-952

RECRUITING

Department of Nephrology, Transplantology and Internal Diseases, Medical University of Gdansk, Gdansk

30-688

NOT_YET_RECRUITING

Clinical Department of Nephrology, Dialysis, Transplantology and Internal Medicine, Krakow

90-153

NOT_YET_RECRUITING

Department of Internal Diseases and Transplant Nephrology, Medical University of Lodz, Lodz

60-479

NOT_YET_RECRUITING

Department of Transplantology and General Surgery, Provincial Hospital, Poznan

02-097

NOT_YET_RECRUITING

Department and Clinic of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw

50-556

NOT_YET_RECRUITING

Department and Clinic of Nephrology and Transplantation Medicine, University Clinical Hospital, Wroclaw

All Listed Sponsors
lead

Chiesi Poland Sp. z o.o.

INDUSTRY